|
Video: What is a Stock Split?
|
|
AtriCure provides treatments for atrial fibrillation (Afib), left atrial appendage management and post-operative pain. Co.'s ablation and left atrial appendage management products are used by physicians during both open-heart and minimally invasive procedures. Co.'s Isolator® Synergy Ablation System is approved by U.S. Food and Drug Administration (FDA) for the treatment of persistent and long-standing persistent Afib concomitant to other open-heart surgical procedures. The EPi-Sense® system is approved by FDA to treat patients with long-standing persistent Afib. All of Co.'s other ablation devices are cleared for sale in U.S., including its other radio frequency and cryoablation products. According to our ATRC split history records, AtriCure has had 1 split. | |
|
AtriCure (ATRC) has 1 split in our ATRC split history database. The split for ATRC took place on February 01, 1996. This was a 1 for 10
reverse split, meaning for each 10
shares of ATRC owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.
When a company such as AtriCure conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the ATRC split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into AtriCure shares, starting with a $10,000 purchase of ATRC, presented on a split-history-adjusted basis factoring in the complete ATRC split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/25/2014 |
|
End date: |
04/23/2024 |
|
Start price/share: |
$16.66 |
|
End price/share: |
$23.17 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
39.08% |
|
Average Annual Total Return: |
3.35% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$13,904.14 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
02/01/1996 | 1 for 10
|
|
|